-
2
-
-
84855964379
-
Multiple sclerosis: New insights in pathogenesis and novel therapeutics
-
Ontaneda D, Hyland M, Cohen JA. Multiple sclerosis: new insights in pathogenesis and novel therapeutics. Annu Rev Med 2012; 63: 389-404.
-
(2012)
Annu Rev Med
, vol.63
, pp. 389-404
-
-
Ontaneda, D.1
Hyland, M.2
Cohen, J.A.3
-
3
-
-
0029852737
-
A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans
-
Isaacs JD, Wing MG, Greenwood JD, Hazleman BL, Hale G, Waldmann H. A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans. Clin Exp Immunol 1996; 106: 427-33.
-
(1996)
Clin Exp Immunol
, vol.106
, pp. 427-433
-
-
Isaacs, J.D.1
Wing, M.G.2
Greenwood, J.D.3
Hazleman, B.L.4
Hale, G.5
Waldmann, H.6
-
4
-
-
84857055778
-
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis
-
Hill-Cawthorne GA, Button T, Tuohy O, et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2012; 83: 298-304.
-
(2012)
J Neurol Neurosurg Psychiatry
, vol.83
, pp. 298-304
-
-
Hill-Cawthorne, G.A.1
Button, T.2
Tuohy, O.3
-
5
-
-
0030177999
-
CAMPATH-IH in multiple sclerosis
-
Moreau T, Coles A, Wing M, et al. CAMPATH-IH in multiple sclerosis. Mult Scler 1996; 1: 357-65.
-
(1996)
Mult Scler
, vol.1
, pp. 357-365
-
-
Moreau, T.1
Coles, A.2
Wing, M.3
-
6
-
-
54949143968
-
Alemtuzumab vs interferon beta-1a in early multiple sclerosis
-
Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786-801.
-
(2008)
N Engl J Med
, vol.359
, pp. 1786-1801
-
-
Coles, A.J.1
Compston, D.A.2
Selmaj, K.W.3
-
7
-
-
80053207130
-
Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort
-
Cossburn M, Pace AA, Jones J, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 2011; 77: 573-79.
-
(2011)
Neurology
, vol.77
, pp. 573-579
-
-
Cossburn, M.1
Pace, A.A.2
Jones, J.3
-
8
-
-
84869492471
-
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial
-
for the CARE-MS I investigators; published online Nov 1
-
Cohen JA, Coles AJ, Arnold DL, et al, for the CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012; published online Nov 1. http://dx.doi.org/10.1016/S0140-6736(12) 61769-3.
-
(2012)
Lancet
-
-
Cohen, J.A.1
Coles, A.J.2
Arnold, D.L.3
-
9
-
-
84869507357
-
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial
-
for the CARE-MS II investigators; published online Nov 1
-
Coles AJ, Twyman CL, Arnold DL, et al, for the CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012; published online Nov 1. http://dx.doi.org/10.1016/S0140-6736(12)61768-1.
-
(2012)
Lancet
-
-
Coles, A.J.1
Twyman, C.L.2
Arnold, D.L.3
-
10
-
-
8844285856
-
Interferon beta-1b in secondary progressive MS: A combined analysis of the two trials
-
Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 2004; 63: 1779-87.
-
(2004)
Neurology
, vol.63
, pp. 1779-1787
-
-
Kappos, L.1
Weinshenker, B.2
Pozzilli, C.3
-
11
-
-
33644608613
-
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
-
Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-23.
-
(2006)
N Engl J Med
, vol.354
, pp. 911-923
-
-
Rudick, R.A.1
Stuart, W.H.2
Calabresi, P.A.3
-
12
-
-
76149140914
-
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
-
Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-15.
-
(2010)
N Engl J Med
, vol.362
, pp. 402-415
-
-
Cohen, J.A.1
Barkhof, F.2
Comi, G.3
-
13
-
-
84861040663
-
Predicting risk of progressive multifocal leukoencephalopathy from natalizumab
-
Ropper AH. Predicting risk of progressive multifocal leukoencephalopathy from natalizumab. N Engl J Med 2012; 366: 1938-39.
-
(2012)
N Engl J Med
, vol.366
, pp. 1938-1939
-
-
Ropper, A.H.1
-
14
-
-
79960344014
-
Natalizumab treatment for multiple sclerosis: Updated recommendations for patient selection and monitoring
-
Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011; 10: 745-58.
-
(2011)
Lancet Neurol
, vol.10
, pp. 745-758
-
-
Kappos, L.1
Bates, D.2
Edan, G.3
-
15
-
-
68849084141
-
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)
-
Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009; 119: 2052-61.
-
(2009)
J Clin Invest
, vol.119
, pp. 2052-2061
-
-
Jones, J.L.1
Phuah, C.L.2
Cox, A.L.3
-
16
-
-
84860780657
-
Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial
-
Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012; 78: 1069-78.
-
(2012)
Neurology
, vol.78
, pp. 1069-1078
-
-
Coles, A.J.1
Fox, E.2
Vladic, A.3
|